Mapping Canadian Provincial Data Assets to Conduct Real-World Studies on Cancer Drugs

CanREValue Collaboration Data Working Group Interim Report 2020
CanREValue Collaboration

Overview of the CanREValue Collaboration

The Canadian Real-world Evidence for Value in Cancer (CanREValue) Collaboration is a pan-Canadian, multi-stakeholder initiative established in 2017 under a Canadian Institutes of Health Research Partnerships for Health System Improvement Grant. Led by Dr. Kelvin Chan, the central project is titled “Developing a framework for the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada.” The goal of the project is to develop and test a framework for the generation and use of RWE for cancer drugs to facilitate:

I. Reassessment of cancer drugs by recommendation-makers; and
II. Refinement of funding decisions, renegotiation of drug prices, or disinvestment as appropriate by decision-makers/payers across Canada.

Once developed, the framework could potentially be used to support evidence-based policy reform, pricing, and reallocation of funding from low- to high-value settings. In addition, the framework could facilitate the accountability and sustainability of the cancer system if used by the provinces and by areas of the healthcare system.

Working Groups

As part of developing the framework, five working groups (WGs) have been established to develop the framework (Figure 1). To ensure the framework can support the needs of various stakeholders, the CanREValue Collaboration brought together a broad range of stakeholders from across different organizations and agencies (Figure 2). The WGs and their key deliverables are listed below.

- **RWE planning and drug selection WG**: Recommend criteria to identify and prioritize potential drug candidates for real-world evidence studies and advise on the necessary provincial infrastructure needed for the conduct of RWE.
- **RWE Data WG**: Recommend strategies for data access and provide advice on the harmonization of data elements relevant for RWE studies across provinces.
- **RWE Methods WG**: Recommend methods to analyze real-world data with methodological rigor.
- **RWE Reassessment and Uptake WG**: Develop a process to incorporate RWE in HTA reassessment and advise on strategies to incorporate RWE results into policy-making.
- **RWE Engagement WG**: Establish mechanisms to ensure that key stakeholders from across all relevant jurisdictions can provide feedback and input into the developments of each WG.
Figure 1: CanREValue Collaboration Working Group (WG) Structure

- RWE Data WG
- RWE Methods WG
- RWE Planning and Drug Selection WG
- RWE Reassessment and Uptake WG
- RWE Engagement WG

Figure 2: CanREValue Collaboration Stakeholders

Legend: CAPCA = Canadian Association of Provincial Cancer Agency; PMPRB = Patented Medicine Prices Review Board; ARCC = Canadian Centre for Applied Research in Cancer Control; CCTG = Canadian Cancer Trials Group; CPAC = Canadian Partnership Against Cancer; pCPA = pan-Canadian Pharmaceutical Alliance; HTA = Health Technology Assessment; pCODR = pan-Canadian Oncology Drug Review; CADTH = Canadian Agency for Drugs and Technologies in Health; INESSS = Institut national d’excellence en santé et services sociaux; OSCCD = Ontario Steering Committee for Cancer Drug;
CanREValue Collaboration: Data Working Group Interim Report

Mapping Canadian data assets to conduct real-world studies on cancer drugs

Authors

Kelvin Chan  
Sunnybrook Odette Cancer Centre  
Canadian Centre for Applied Research in Cancer Control

Claire de Oliveira (Chair of Data Working Group)  
Centre for Addiction and Mental Health  
University of York

Wei Fang Dai  
Cancer Care Ontario, Ontario Health  
Canadian Centre for Applied Research in Cancer Control

Jaclyn Beca  
Cancer Care Ontario, Ontario Health  
Canadian Centre for Applied Research in Cancer Control

Rebecca Mercer  
Cancer Care Ontario, Ontario Health  
Canadian Centre for Applied Research in Cancer Control

Wanrudee Isaranuwatchai  
St Michael’s Hospital  
Canadian Centre for Applied Research in Cancer Control

Mina Tadrous  
Women’s College Hospital

Bill Evans  
McMaster University

Reka Pataky (Data Working Group Member)  
BC Cancer  
Canadian Centre for Applied Research in Cancer Control

Winson Cheung (Data Working Group Member)  
University of Calgary  
CancerControl Alberta

Riaz Alvi (Data Working Group Member)  
Saskatchewan Cancer Agency

David Tran (Data Working Group Member)  
Saskatchewan Cancer Agency

Donna Turner (Data Working Group Member)  
CancerCare Manitoba

Zeb Aurangzeb (Data Working Group Member)  
CancerCare Manitoba

Carrie O’Conaill (Data Working Group Member)  
CancerCare Manitoba

Nicole Mittmann (Data Working Group Member)  
CADTH

Erin Strumpf (Data Working Group Member)  
McGill University  
Institut national d’excellence en santé et services sociaux

Ted McDonald (Data Working Group Member)  
University of New Brunswick,  
New Brunswick Research Data Centre

Farah McCrate (Data Working Group Member)  
Eastern Health

Jeff Dowden (Data Working Group Member)  
Eastern Health

Robin Urquhart (Data Working Group Member)  
Dalhousie University

Philip Champion (Data Working Group Member)  
Prince Edward Island Cancer Treatment Centre

Kim Vriends (Data Working Group Member)  
Prince Edward Island Cancer Treatment Centre

Carol McClure (Data Working Group Member)  
Prince Edward Island Cancer Treatment Centre
# Table of Contents

**Contents**

Table of Contents .................................................................................................................. 5

Executive Summary .............................................................................................................. 6

Introduction ........................................................................................................................... 7

Section I: Provincial data custodians & databases ................................................................. 8

Section II: Data elements for conducting real-world studies .............................................. 14

Section III: Provincial capability and capacity assessment ................................................. 24

Next steps .............................................................................................................................. 25

References: .......................................................................................................................... 26
Executive Summary

The generation of robust real-world evidence (RWE) depends heavily on the availability and quality of real-world data (RWD). In Canada, provinces routinely collect patient-level data during patient care. These RWD can be used to generate valuable RWE to inform clinical care and healthcare policy. This report describes the CanREValue Data Working Group’s efforts to map the currently available population-based provincial data assets in Canada. The report provides a high-level assessment of databases and data elements relevant to the conduct of cancer-specific RWE studies in each province.

Section I: This section identifies the key data custodians in each province that hold and maintain databases required to conduct real-world analysis. Given our focus is on publicly funded cancer drugs, descriptions of the funding model in each province are also included. The main findings include the following:

- Databases are often held by multiple data custodians, such as provincial ministries/departments of health and provincial cancer agencies. These organizations are typically the administrators of a particular healthcare treatment or service or associated funding.
- The funding model for cancer drugs often varies by provinces, especially with respect to the coverage of intravenous and oral cancer drugs.
- In some provinces, third-party organizations may also act as data custodians and can facilitate linkages between datasets.

Section II: This section focuses on the variables and data elements that would be commonly required to describe a cohort and conduct a real-world study. Data experts from each province reviewed their provincial databases to determine whether relevant data elements were available and linkable, along with any limitations in coverage and/or completeness of the data. From this asset review, we compiled two data tables:

- **The Expanded Cancer RWD table** consists of potentially relevant data elements for addressing a variety of RWE questions. The availability and linkability of the data elements varies between provinces.
- **The Essential Cancer RWD table** contains a subset of data elements from the Expanded Cancer RWD table. This data table lists variables required to identify a cohort and answer specific descriptive or comparative RWE questions. The variables included are broadly available across provinces.

Section III: This section outlines each province’s assessment of their capability to conduct real-world analysis for different outcomes (e.g. effectiveness, safety). Additionally, the provinces also estimated their capacity to generate RWE based on resourcing. Our main findings are as follows:

- Canadian provinces differ in their capability to identify and evaluate different cancer treatment outcomes based on available data elements.
- Most provinces can conduct an RWE analysis on the outcomes they have data elements for within 6 – 12 months, if additional resourcing is provided.

Building upon the findings from this report, we have initiated RWE projects across Canada to assess the real-world outcomes of a funded cancer drug. We will iteratively update the data tables in this report based on the learnings from the RWE analyses. Through this iterative process, we will gain a fundamental understanding of the RWD assets that can be used to conduct RWE analysis.
Introduction

In Canada, provinces routinely collect patient-level data during patient care for administrative purposes. These real-world data (RWD) can be used to generate robust real-world evidence (RWE) that can inform clinical care and healthcare policy. In particular, RWE generated on funded cancer drugs can be used to monitor outcomes and revisit drug funding decisions. Given that the generation of robust RWE depends heavily on the availability and quality of RWD, it is critical to understand the current data assets available in Canada.

Overview of CanREValue Data Working Group

The CanREValue Data Working Group (WG) was established to explore the current state of data readiness for RWE analyses in Canada. The primary objective of the working group is to identify the availability and accessibility of RWD relevant for cancer-specific real-world studies across Canadian provinces.

Chaired by Dr. Claire de Oliveira, the working group consists of data experts/researchers from across the 10 Canadian provinces. During the first two years of the project (2017-2019), the WG held three teleconferences and met twice in-person to discuss the data elements necessary to conduct RWE studies. Through an iterative discussion, the WG members completed a data asset review in each of their provinces. The members compiled information on available databases, the status of the data elements maintained in the databases, and the capability of conducting RWE studies based on available data and resources.

Data Working Group Report:

In 2018, the Canadian Institute for Health Information (CIHI) released the pan-Canadian Oncology Drug Data Minimum Data Set report, which outlined a consistent data standard for collecting oncology drug data elements necessary to study oncology drugs. The data elements listed by CIHI must be present to identify treatment exposure and patient demographic and diagnostic information. However, there may be more detailed information required to determine treatment patterns, conduct robust comparative analyses and assess a variety of outcomes, including linkage to additional databases beyond the scope of treatment data outlined by the CIHI report. Our report complements the previous work described in the CIHI report by providing additional information on data holders and data holdings, a broader list of data elements that are desired to conduct real-world studies and assessment of data availability across provinces.

This report presents the findings from the initial scoping assessment of data availability conducted by each provincial representative on the CanREValue Data WG. The first section of the report focuses on the data holdings in each province. Given the focus is on publicly funded cancer drugs, this section also outlines how cancer treatments are funded in each province to provide context and address coverage. The second section describes the data elements required to generate RWE and presents two data tables, which outline the availability of these RWD elements by province. In the last section, we present assessments of capability and capacity to conduct real-world studies by province.
Section I: Provincial data custodians & databases

This section presents provincial data custodians and the databases they maintain or hold that are available to conduct cancer-specific RWE analyses. While the focus is on cancer-related databases, we also present non-cancer databases because they capture variables integral to conducting a robust RWE study. Given that we are interested in conducting population-based RWE studies on funded cancer drugs, we have focused on the databases that are maintained or held by public organizations.

Since we focus on conducting RWE on publicly funded cancer drugs, we also present the cancer drug funding model in each province. In general, eligible patients can access funded cancer drugs listed on the public formularies through the provincial drug reimbursement programs. Some provinces have one provincial funding program for cancer drugs, while other provinces have multiple provincial funding programs. In provinces with multiple provincial funding programs, they may differ based on route of administration or distribution setting and criteria for eligibility.

This section of the report is divided into two parts. The first part is a summary of the main findings. The second part describes the funding model and the main data custodians for each province. For details on each of the databases, please see Appendix Section 1.

Part 1: Summary of Main Findings

The CanREValue Data WG identified 96 databases across Canada. Provinces held on average 9 (range: 8 – 12) distinct databases containing data elements relevant for cancer-specific RWE analysis. In most provinces, databases are held by multiple data custodians, which include Ministries/Departments of Health (MoH/DoH) and provincial cancer agencies. In most provinces, cancer treatment is organized through provincial cancer agencies, which also maintain population-based cancer-related databases, such as the provincial cancer registry. In other provinces, the MoH/DoH maintains databases on all healthcare treatments (cancer and non-cancer) and services administered through provincial health insurance plans.

In most provinces, the MoH/DoH works with CIHI to capture data on hospitalizations through the Discharge Abstract Database (DAD), and data on emergency department visits through the National Ambulatory Care Reporting System (NACRS). The level of reporting to CIHI varies by province and over time. All provinces, with the exception of Québec, fully report to the DAD; however, only Ontario and Alberta currently fully report to the NACRS.

In some provinces, there are also third-party organizations (e.g. ICES in Ontario) designated as data custodians. These organization have been granted privacy authority to access and link provincial demographic and health-related databases for research and evaluation.
Part 2: Provincial Data Holdings and Cancer Funding Models

British Columbia (BC):

BC Cancer is the provincial cancer agency that administers funding for systemic therapies for cancer treatment through the Provincial Systemic Therapy Program (PSTP). The PSTP maintains a Benefit Drug List of all funded drugs and approved treatment protocols, and includes all approved cancer therapies, regardless of route of administration or treating facility, including intravenous drugs delivered in hospital or ambulatory clinics, and outpatient oral/take-home drugs. Supportive care medications are not covered through the PSTP. All patients with a registered cancer diagnosis enrolled in the BC Ministry of Health’s Medical Services Plan (MSP) are eligible for the program. For many newly-funded drugs or indications, coverage is also contingent on the approval of a Compassionate Access Program application to verify the patient’s clinical eligibility. The full cost of benefit drugs is borne by BC Cancer. The cost of drugs for patients treated at Community Oncology Network sites, outside BC Cancer’s regional cancer centres, is submitted for reimbursement by the treating facility.

The main data custodians are BC Cancer, the BC Ministry of Health, and the BC Vital Statistics Agency. BC Cancer holds the BC Cancer Registry, the BC PSTP database, the BC Cancer Radiotherapy database, the BC Cancer Surgery database, and the BC Cancer Cancer Agency Information System CAIS Scheduling database. The BC Ministry of Health holds the MSP registration database, the MSP payment information file, the PharmaNet database, the Home and Community Care database, the Discharge Abstract Database, and the National Ambulatory Care Reporting System database. The BC Vital Statistics Agency holds the Vital Statistics Death file, which can be accessed via Population Data BC. The BC Cancer data holdings can be accessed internally within BC Cancer, or linked to BC Ministry of Health and de-identified for research purposes via Population Data BC.

Alberta (AB):

Cancer care in Alberta is largely managed and governed under the auspices of CancerControl Alberta, which represents a distinct branch of Alberta Health Services (AHS), the province’s sole health authority. Decisions regarding the public funding of cancer drugs, for both intravenous and oral agents, are mainly based on recommendations from the Cancer Drugs Evaluation committee. The delivery of these drugs is operationalized in 17 cancer centres across the province. Currently, there are two tertiary, four regional, and eleven community cancer sites in Alberta. Cancer drugs covered by AHS are provided to eligible individuals in Alberta through the Outpatient Cancer Drug Benefit Program (OCDBP). Individuals are eligible to receive treatment through either intravenous or oral cancer drugs if they are Alberta residents, have a valid Alberta health card, and meet the therapeutic eligibility guidelines set out by the appropriate provincial tumour teams.

The main custodians are AHS and Service Alberta. Alberta Health Services holds both cancer- and non-cancer-related databases including the Alberta Cancer Registry, the Oncology-Specific Clinical Information System, the Pharmaceutical Information Network, Alberta Blue Cross Claims, Population Registry, Practitioner Claims, the Discharge Abstract Database, the National Ambulatory Care Reporting System database, and the Alberta Continuing Care Information System. Service Alberta holds the vital statistics files that can be accessed to obtain information on birth and death dates. When conducting RWE studies in Alberta, these databases can be accessed via AHS.
**Saskatchewan (SK):**

The Saskatchewan Cancer Agency (SCA) administers cancer treatments for patients through funding from the government of Saskatchewan. The SCA drug formulary provides a list of anti-cancer drugs and some supportive drugs provided free of charge for eligible patients with a valid Saskatchewan health card and that are registered with SCA. This list includes both oral and intravenously administered drugs. All formulary cancer drugs provided on an outpatient basis are dispensed by cancer centre pharmacies located in the Allan Blair Cancer Centre (Regina) or the Saskatoon Cancer Centre. This includes cancer drugs administered at the two tertiary cancer centres and by the Community Oncology Program of Saskatchewan centres. All formulary cancer drugs, injectable or oral cancer treatments are dispensed by Cancer Agency Pharmacies to the hospital for administration. Supportive care therapies, with a few exceptions (e.g. filgrastim, G-CSF), are generally provided by the hospital and not funded by the SCA.

The main data custodians are the SCA and the Saskatchewan Ministry of Health. The SCA database holdings include the SK Cancer Registry, the Pharmacy oncology database, the Medical Oncology database and the Radiation Oncology database. The Saskatchewan Ministry of Health holds the Physician Claims database, the Discharge Abstract Database, the National Ambulatory Care Reporting System database, and the Continuing Care Reporting System. The SCA data holdings can be accessed internally. Data holdings from Saskatchewan Ministry of Health can also be accessed for research purposes through the SCA.

**Manitoba (MB):**

In Manitoba, intravenous and oral cancer drugs are administered by different programs. The provincial cancer agency, CancerCare Manitoba, administers intravenous cancer drug funding through the Provincial Oncology Drug Program (PODP), which was created by the Ministry of Health, Seniors and Active Living in 2006. The program directly covers the full drug costs of all the approved intravenous cancer drugs and necessary support drugs administered in hospitals and outpatient cancer facilities across Manitoba. Oral cancer drugs are covered under the provincial Home Cancer Drug (HCD) Program. Created in 2012, the Home Care Drug Program is a publicly funded program of the Ministry of Health, Seniors and Active Living. The program directly covers the full costs of all approved oral cancer and supportive care drugs in Manitoba. Individuals qualify for both programs if they are residents of Manitoba and have a valid Manitoba health card. Cancer drug approval in Manitoba mirrors the national process of cancer drug approval, through the pan-Canadian Oncology Drug Review, and other national bodies, with input from the local Medication Management and Safety Committee.

The main data custodians are CancerCare Manitoba and the Ministry of Health, Seniors and Active Living. CancerCare Manitoba holds the PODP database, the HCD database, the Manitoba Cancer Registry database, and the Radiation Oncology database. The Ministry of Health, Seniors and Active Living holds the Manitoba Health Insurance Plan database, the Drug Program Information Network database, the Medical Claims database, the Discharge Abstract Database, and the National Ambulatory Care Reporting System database. The databases can be assessed internally through CancerCare Manitoba.
**Ontario (ON):**

In Ontario, funding for intravenous and oral cancer drugs are administered by different programs under the Ontario Public Drug Programs (OPDP) at the Ministry of Health (MOH). Intravenous cancer drug funding is administered by Cancer Care Ontario (CCO), the provincial cancer agency, now part of Ontario Health, on behalf of the MOH through the New Drug Funding Program (NDFP). The program directly covers the full drug cost of intravenous cancer drugs on its formulary that are administered at outpatient ambulatory clinics in hospitals and cancer centres in Ontario. Individuals qualify for the NDFP if they are a resident of Ontario, have a valid Ontario health card, and meet clinical eligibility criteria for the specific funded intravenous cancer drugs and indications requested. The Ontario Drug Benefit (ODB) Program at the MOH covers most of the cost of drugs dispensed in outpatient cancer or community pharmacies for take home use, such as orally administered cancer drugs, for eligible beneficiaries. People are eligible for the ODB program if they are Ontario residents with a valid health card, under the age of 25 (without health insurance coverage) or over the age of 65 years, on social assistance, residing in homes for special care and long-term care homes, receiving professional home care services, or registrants in the Trillium Drug program (subject to income criteria). Costs for take-home cancer drugs not listed on the ODB formulary may be covered, on a case-by-case basis, through the Exceptional Access Program (EAP). Finally, older systemic intravenous treatments administered in a hospital setting may also be paid for through hospital budgets or through CCO’s Systemic Treatment – Quality Based Procedures (ST-QBP).

In Ontario, the main data custodians are CCO, now part of Ontario Health, and the MOH. CCO maintains the NDFP database, along with the Activity Level Reporting System database (capturing cancer-related activities from hospitals, including systemic treatment and ST-QBP data, radiotherapy and surgery), the Ontario Cancer Registry, and the Symptom Management database. The MOH maintains the Registered Persons Database, a population registry on insured persons, the Ontario Health Insurance Plan physician billings database, the ODB claims database, and the Home Care Database. These databases as well as the Discharge Abstract Database and National Ambulatory Care Reporting System database are housed at CCO and at ICES and can be linked for research purposes.

**Québec (QB):**

In Québec, the Public Prescription Drug Insurance Plan, administered by the Régie de l’assurance maladie du Québec (RAMQ) provides basic drug coverage for all Québécois. Individuals are eligible if they do not have a private prescription drug insurance plan, are over the age 65, or require financial assistance. Prescription drugs covered by RAMQ are listed on the List of Medications. Many drugs used to treat cancer are approved for coverage only under certain conditions, as exceptional medications. These exceptional medications and their recognized indications for payment are included in the List of Medications under a separate appendix.

The main data holders are RAMQ, the Ministère de la Santé et des Services Sociaux du Québec, and the Institut de la Statistique du Québec. RAMQ database holdings include the Fichier d’inscription des personnes assurées, the Services rémunérés à l’acte, the Fichier d’admissibilité au régime général d’assurance médicaments, and the Services pharmaceutiques. In addition, RAMQ also hold certain Ministère de la Santé et des Services Sociaux du
Québec databases including the Maintenance et exploitation des données pour l'étude de la clientèle hospitalière, the Banque de données communes des urgences, and the Système d'information sur la clientèle et les services des CSSS (mission CLSC). The Ministère de la Santé et des Services Sociaux du Québec database holdings include the Performance hospitalière, the Fichier des tumeurs, and the Registre québécois du cancer. The Institut de la statistique du Québec holds the Fichier des décès, which can be used as the vital statistics file. Data availability indicated here reflects access via the Institut national d’excellence en santé et services sociaux.

**New Brunswick (NB):**

In New Brunswick, injectable and oral cancer drugs are funded through different mechanisms. Injectable oncology drugs administered in hospitals and outpatient cancer treatment facilities are funded by the Regional Health Authorities for all residents who have a valid New Brunswick Medicare card and meet clinical eligibility criteria. The New Brunswick Department of Health provides funding to the Regional Health Authorities for new injectable oncology drugs. Oral cancer drugs and supportive care medications are covered by the New Brunswick public drug plans for eligible beneficiaries that include seniors, clients of the Department of Social Development, nursing home residents and individuals who do not have public or private drug insurance. The New Brunswick Drug Plans Formulary lists the specific drugs, and any clinical eligibility criteria, covered for eligible beneficiaries.

The main data custodian is the New Brunswick Department of Health. Databases held there include the NB Cancer Treatment Access Repository, the Citizen Database, the NB Cancer Registry, the NB Physician Billing database, the NB Drug Plans Claims database, the Drug Information System Database, the NB Long-term care database, and the Discharge Abstract Database.

**Newfoundland and Labrador (NL):**

In NL, the Newfoundland and Labrador Hospital Insurance Plan is a publically funded program that covers insured inpatient and outpatient services administered at hospital-based settings. Eligibility for coverage under the Hospital Insurance Plan (HIP) is linked with eligibility for coverage under the Newfoundland and Labrador Medical Care Plan (MCP). All beneficiaries of the MCP are automatically entitled to coverage under the HIP. Funding for cancer drugs in NL varies depending on whether the drug is intravenous while oral drugs are funded by two different programs. Intravenous cancer drugs are administered by the NL Cancer Care Program at regional centres and hospitals across the province. Each funded drug and indication has a set of specific eligibility criteria. Intravenous cancer drugs are fully funded for residents with valid MCP coverage who meet the clinical eligibility criteria for the requested drug. Individual requests for non-funded intravenous cancer drugs may be considered by the NL Cancer Care Program on a case-by-case basis. Oral cancer drugs are funded for residents through the Newfoundland and Labrador Prescription Drug Program (NLPDP), which provides financial assistance for the purchase of eligible prescription medications. Individuals are automatically eligible for drug coverage under the NLPDP if they are residents of NL, have a valid health card, and are in receipt of income support benefits, Guaranteed Income Supplement payment or Old Age Security benefits, or are diagnosed with Cystic Fibrosis or Growth Hormone Deficiency and meet medical criteria. People may also be eligible dependent on their income or if they have high drug costs in relation to income.
In NL, the main data holders include the NL Cancer Care Program, the NL Centre for Health Information, and the regional health authorities including Eastern Health, Central Health, Western Health, and Labrador Grenfell Health. The NL Cancer Care Program holds the Medical Oncology database, the Radiation Oncology database, the Provincial Cancer Registry, the Provincial Systemic Therapy database, and the Oncology Patient Information System (OPIS) database. The NL Centre for Health Information holds databases including the Pharmacy Network, the NLPDP database, and Medical Care Plan Billing database. The health authorities maintain their own Meditech electronic health records databases.

**Nova Scotia (NS):**
Intravenous and oral cancer drugs are administered by the Nova Scotia Health Authority (NSHA)’s Cancer Care Program. Nova Scotia Pharmacare provides residents of Nova Scotia assistance with the costs of drugs, including cancer drugs, listed in the Nova Scotia Formulary. The various assistance programs under the Nova Scotia Pharmacare have different eligibility criteria. In February 14, 2018, Nova Scotia Health Authority’s Cancer Care Program established the Take Home Care Drug Fund to provide assistance to patients requiring oral cancer treatment.

The main data custodians are the Nova Scotia Health Authority and the Nova Scotia Department of Health and Wellness; however, Health Data Nova Scotia (HDNS) is designated as an ‘agent’ of the Department of Health and Wellness. As such, HDNS holds a variety of population-based administrative health databases and is responsible for regulating access to these databases for research purposes. Databases held by the Nova Scotia Health Authority include the Nova Scotia Cancer Registry, the Oncology Patient Information System (OPIS), the Physician Billings database, the Discharge Abstract Database, the Seniors Pharmacare Program, and the Drug Information System.

**Prince Edward Island (PEI):**
In PEI, intravenous cancer drugs approved for funding are provide in the cancer center at no charge to the patient. Intravenous drugs funded by private insurance, cash, or industry compassionate programs can also be provided at the cancer center at no charge. Oral cancer agents and home supportive drugs are funded through several means. Most new expensive home drugs are funded for all ages through an income-based High Cost Drug program, which can have a large co-pay requirement. Some are available through the Seniors, Financial Assistance and Family Health Benefit pharmacare programs with a small fee for some of the plans. For younger patients without private insurance, drugs that are off-patent may be funded through the Generic Drug plan with a small co-payment. The Catastrophic drug program is available to all Islanders. The proportion of drug costs covered is based on the patient’s income. PEI requires individuals’ private insurance to pay first for home medications, if the drug is included in their private policy.

The main data holder in PEI is Health PEI. Health PEI holds the PEI Cancer Registry, the Drug Information System, the PEI Cancer Treatment Centre, the Discharge Abstracts Database, Physician Billing System, the Provincial Pharmacy database, and the Clinical Information System.
Section II: Data elements for conducting real-world studies

This section describes the data elements required for the conduct of a real-world study. As a guide to the type of data required, we introduce the three main components of a real-world study: cohort creation, identifying baseline demographic and clinical characteristics for comparability and covariate adjustments, and outcomes to be studied. For each component, we list common and relevant variables that should be used.

Building from the real-world study components from a previous RWE study conducted in Ontario, Saskatchewan, and British Columbia (funded by the Canadian Partnership Against Cancer), the CanREValue core team compiled a list of data elements required for RWE analysis. The data experts from each province were asked to identify the database that contains the variable, an assessment of whether the data element is available and linkable, and any limitations in coverage and/or completeness. The compiled data table from all provinces is the Expanded Cancer RWD Table (Table 1). At the 2019 in-person meeting, the CanREValue Data Working Group identified a list of variables that are essential to generate RWE and are available in all provinces. The purpose was to create a list of variables that are minimally necessary in order to conduct a real-world study. This compiled data table is the Essential Cancer RWD Table (Table 2).

This section of the report is divided into two parts. The first part is a summary of the components of a real-world study and the variables relevant for each component. The second part consists of details on the two data tables. For details on each data element, please see Appendix Section 2.

Part 1: Real-world Study Components:

To conduct a real-world study, researchers need to build an appropriate study cohort, identify potential demographic and clinical characteristics to describe the cohort and use as covariates to adjust for differences between groups, and identify appropriate outcomes of interest.

Cohort Creation:
- Variables to identify the disease of interest: morphology, topography, behaviour, stage, date of diagnosis;
- Variables to identify treatments of interest: treatment received (drug, regimen/protocol), indication/line of therapy, intent of treatment, date of treatment, route of administration.

Demographic and Clinical Characteristics:
- Baseline demographic and clinical variables: age, sex, neighbourhood income quintile, rurality, comorbidity, performance status, prior treatments (systemic, radiotherapy, surgical);
- Subsequent treatments: chemotherapy, radiotherapy, cancer-directed surgery.
Outcomes

(I) Clinical Effectiveness: When stakeholders are interested in assessing real-world effectiveness, survival analyses can be performed.
   - Overall survival: first date of treatment, date of death, study end date/date of last contact with the healthcare system
   - Other time-to-event endpoints (if available): first date of treatment, date of event of interest (e.g., treatment discontinuation, progression etc.), study end date, date of last contact with the healthcare system

(II) Safety & Toxicity: Real-world safety of a drug can be assessed by determining the occurrence of hospitalisations or emergency department visits during or following the treatment period.
   - Hospitalisations and/or emergency department visits: date of visit, reason for visit

(III) Cost-Effectiveness: The real-world cost-effectiveness of a treatment can be determined using estimates from an effectiveness analysis combined with a costing analysis. Data required for effectiveness analyses are listed above. In order to conduct costing analyses, comprehensive data on the cost accrued by the patient are required.
   - Sources of cost data: systemic therapy drugs, radiotherapy, surgical treatment, hospitalisations, same-day surgeries, physician services, outpatient prescription drugs, home care, palliative care, continuing and long-term care (where available), other ambulatory care (where available)

(IV) Budget Impact: To undertake a budget impact analysis from the third party public payer’s perspective, population treatment patterns and spending are required
   - Cost of drug, number of patients per year, height of patient, weight of patient, dose per patient, dose per cycle, cycles per patient, treatment duration, market size (number of patients eligible for treatment), and market share (% of patients receiving drug of interest)

(V) Patient Reported Outcomes: When information from patients is collected in a setting that assesses their symptoms or quality of life, this information can complement the analysis above. For example, patient-reported quality of life utilities can be used to calculate quality adjusted life years (QALYs).
   - Patient-reported assessments of quality of life or symptoms

When conducting a real-world study, it is important to ensure that sufficient follow-up data are available to assess the outcome and endpoint of interest.
Part 2: Real-world Data elements:

Expanded Cancer RWD Table:

The Expanded Cancer RWD Table, presented in Table 1, is a data asset inventory on a generic list of variables relevant for the conduct of real-world studies. While some of the variables listed in Table 1 can be captured by one data element (e.g. sex), other variables are derived from multiple data elements (e.g. age at first treatment, which requires date of birth and treatment date). Details for each variable are listed in the description column.

This list of variables was developed from a previous population-based real-world evidence study conducted in British Columbia, Saskatchewan, and Ontario. There may be additional variables that are relevant for a specific drug or disease that are not listed (e.g. disease- or drug-specific biomarkers). These variables will need to be assessed on a case-by-case basis when undertaking a specific evaluation. Additionally, variables that are not routinely collected or reported to population-based databases stored by public organizations are also currently not included from this list, but may be considered for future iterations.

While most provinces have data on patient demographics (e.g. age, sex) and cancer diagnosis related variables (e.g. morphology, topography), the availability and linkability of data on cancer treatment, clinical characteristics, and drug costs varies among provinces. Additional details regarding data elements can be found in Appendix Section 2.

Cancer drug treatment data:

When attempting to identify the data relevant for identifying cancer treatments, we found that the treatment data available in provincial databases differ across the provinces. One notable factor of this difference is the route of administration (e.g. oral or intravenous). In the section below, we will provide a brief description the treatment data that are available across the provinces:

- **BC**: In BC, data on both oral and intravenous (IV) cancer drugs are captured by the provincial BC Cancer Provincial Systemic Therapy Program database. For intravenous and oral drugs, data elements such as drug name, drug identification number (DIN), treatment date and dose per treatment are collected. For oral drugs data elements such as drug name, DIN, dispensing date, total quantity dispensed and days supplied are collected. The treatment data collected reflects what was dispensed/administered, and not what was planned/prescribed.

- **AB**: In AB, data on both oral and intravenous cancer drugs are captured by the Pharmaceutical Information Network and the Alberta Cancer Registry, respectively. For oral drugs, data elements such as drug name, DIN, order date, dispensing date, total quantity dispensed, days supplied and refills dispensed are collected. For intravenous drugs, data elements such as regimen name, drug name, DIN, treatment date and dose per treatment are collected.

- **SK**: In SK, data on both oral and intravenous cancer drugs are captured by SK Cancer Agency. For intravenous drugs, data elements such as drug name, DIN, treatment date and dose per treatment are collected. For oral drugs data elements such as drug name, DIN, order date,
dispensing date, total quantity dispensed, days supplied and refills dispensed are collected. Additionally, both dispensed/administered and planned/prescribed information are collected.

- **MB**: Data on intravenous cancer drugs are captured by CancerCare Manitoba (CCMB) in the ARIA-MO, whereas data on oral cancer drugs are captured in Manitoba Health Drug Program Information Network (DPIN) database. The data element captured for the intravenous drugs include elements such as drug name, DIN, treatment date at which the drug was administered and the administered and dose. For oral drugs, data elements such as drug name, DIN, dispensing/provision date, metric quantity claimed, drug cost claimed, professional fee claimed and days supplied.

- **ON**: In ON, data on oral and intravenous cancer drugs are captured by separated databases. Intravenous cancer drugs are captured by the New Drug Funding Program (NDFP) database; data elements such as policy name, drug name, treatment date and dose per treatment are collected. Data on oral cancer drugs are captured by the Ontario Drug Benefit (ODB) program; data elements such as drug name, DIN, dispensing date, quantity dispensed, and days supplied are collected. In addition, the Activity Level Reporting System databases also captures data on both intravenous and oral cancer treatments received from NDFP and ODB, in addition to those received from clinical trials.

- **QB**: In QB, the pharmacy database from the Régie de l’assurance maladie du Québec includes prescriptions filled in community pharmacies and paid for by the RAMQ, therefore oral and not IV chemotherapy. Data elements such as drug name, chemotherpay treatment codes, dispensing dates, and quantity dispensed are collected. Further exploration of these data elements is required to judge their quality for analyses.

- **NL**: In NL, data on oral and intravenous cancer drugs are captured by separate databases. Intravenous cancer drugs are captured by the Provincial Systemic Therapy database; data elements such as drug name, line of therapy, treatment date and dose per treatment are collected. Data on some oral cancer drugs are captured by the NL prescription drug program as drug name, DIN, dispensing date, quantity dispensed, and days supplied are collected.

- **NS**: In NS, population-based oral and intravenous treatment data are not available. However, the hospital pharmacy database in the central zone of the Nova Scotia Health Authority captures all oral and intravenous drugs dispensed by the pharmacy for in-hospital use. It is estimated that this database captures cancer treatment information for approximately half of the province’s population. Data available from the hospital pharmacy database include drug name, whether the drug is administered orally or through intravenous, dose or quantity dispensed, dispensing date, and, to a limited extent, treatment intent. Cancer treatments administered intravenously are captured, however, since this is a hospital pharmacy database; oral chemotherapy prescribed to patients for use outside of the hospital setting is not captured.

- **NB**: In NB, data on oral and intravenous cancer drugs are captured by separated organizations. Intravenous drugs are administered in hospitals and ambulatory care clinics. These data are collected and can be accessed by organizations such as Vitalité Health Network and Horizon Health Network. Data elements captured include drug name, treatment date, and dose per
Data elements for RWE studies
CanREValue Interim Data Report: 2020 version

- **treatment.** Data on oral cancer drugs are captured by the NB Drug Plans Claims database; data elements such as drug name, DIN, dispensing date, quantity dispensed, and days supplied are collected.

  - **PEI:** In PEI, data on provincial Data on intravenous and oral cancer drugs administered at Cancer Treatment Centres are captured by the clinical information system. Data elements such as drug name, DIN, treatment date and dose per treatment are collected. Data on oral cancer drugs, including filled at community pharmacies are captured in the Drug Information System with data elements such as drug name, DIN, dispensing date, total quantity dispensed and days supplied are collected.

In most provinces, additional data elements such as order date or planned cycles for cancer drugs may be available in patient charts. Given that they are not recorded in electronic databases, chart reviews and abstractions must be conducted to retrieve these data.

**Essential Cancer RWD Table:**

The Essential Cancer RWD Table (Table 2) includes the minimally necessary data elements needed for real-world studies. The data elements listed in this table are available in all ten provinces. Additionally, when conducting an RWE analysis, these data elements are required for both descriptive and comparative analyses.
# Table 1: Expanded Cancer RWD Table

<table>
<thead>
<tr>
<th>Category</th>
<th>Variables</th>
<th>Description</th>
<th>BC</th>
<th>AB</th>
<th>SK</th>
<th>MB</th>
<th>ON</th>
<th>QB</th>
<th>NB</th>
<th>NS</th>
<th>NL</th>
<th>PEI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cohort Creation: Identify disease of interests</td>
<td>Topography</td>
<td>ICD-O-3 Code from the International Classification of Diseases to identify the part of the body affected by disease or the site of origin of the neoplasm</td>
<td>?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Morphology</td>
<td>ICD-O-3 Code from the morphology section of the International Classification of Diseases to identify the microscopic structure of cells, tissues, and organs</td>
<td>?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Behaviour</td>
<td>Reportable histological behaviour – the 5th digit of reported histology, based on reported site</td>
<td>?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stage</td>
<td>Stage at diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Date of diagnosis</td>
<td>Provide date of first diagnosis of the primary site of cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cohort Creation: Identify treatment of interest</td>
<td>Drug Identifier – IV</td>
<td>Identifies IV drug received by patient</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Drug Identifier – Oral</td>
<td>Identifies oral drug received by patient</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treatment Indication</td>
<td>Identifies specific indication for use</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Intent of treatment</td>
<td>Adjuvant, curative, or palliative</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Line of therapy</td>
<td>Line of therapy such as first-line setting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Date of treatment administration</td>
<td>Date of treatment for particular IV drug</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dispensing date</td>
<td>Dispensing date for particular oral drug</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographic and Clinical Characteristics</td>
<td>Provincial Patient Identifier</td>
<td>Unique patient identifier</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sex</td>
<td>Patient Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Date of Birth</td>
<td>Patient date of birth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Age at first treatment</td>
<td>Age at first treatment is derived from date of birth and date of treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Postal Code</td>
<td>Patient’s postal code of residence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rural/Urban residence</td>
<td>Urban or rural residence determined from the patient’s postal code</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neighbourhood Income Quintile</td>
<td>Neighbourhood level income determined using Statistics Canada’s macro and postal code</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Regional Health Authority</td>
<td>Health authority region of patient’s residence (if applicable)</td>
<td>N/A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Charlson’s Score</td>
<td>Co-morbidity measure derived from hospitalizations data and reasons for admission</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adjusted Clinical Groups(ACG)</td>
<td>Co-morbidity measure using the John Hopkin’s ACG system and derived from hospitalization data, reasons for admission, physician visits, and ED visits</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Category</td>
<td>Variables</td>
<td>Description</td>
<td>BC</td>
<td>AB</td>
<td>SK</td>
<td>MB</td>
<td>ON</td>
<td>QB</td>
<td>NB</td>
<td>NS</td>
<td>NL</td>
<td>PEI</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>-----</td>
</tr>
<tr>
<td>ECOG-Performance Status</td>
<td>Performance Status</td>
<td>Performance Status</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Palliative Performance Status</td>
<td>Performance Status</td>
<td>Performance Status</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Radiotherapy Use</td>
<td>Identifies patients who received radiotherapy</td>
<td>Dose of radiotherapy delivered</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Radiotherapy – Dose/minutes per fraction</td>
<td>Dose of radiotherapy delivered</td>
<td>härogeny</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Radiotherapy – Intent</td>
<td>Intent of radiotherapy treatment as determined by the radiation oncologist at the time of booking of the planning/treatment visit. (e.g. adjuvant, curative)</td>
<td>Intent of radiotherapy treatment as determined by the radiation oncologist at the time of booking of the planning/treatment visit. (e.g. adjuvant, curative)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Radiotherapy – visit date</td>
<td>Patient’s visit date for radiotherapy treatment</td>
<td>Patient’s visit date for radiotherapy treatment</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Surgical resection code</td>
<td>CIHI CCP/CCI procedure code describing the procedure administered to the patient</td>
<td>CIHI CCP/CCI procedure code describing the procedure administered to the patient</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Surgical resection date</td>
<td>Date of surgical intervention associated with CCP/CCI codes</td>
<td>Date of surgical intervention associated with CCP/CCI codes</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Clinical Effectiveness</td>
<td>Date of Death</td>
<td>Date of death</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Date of last contact</td>
<td>Variable derived from dates of healthcare service utilization (e.g. discharge date, date of last treatment)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Safety &amp; Toxicity</td>
<td>ED Visit - Date of registration&lt;sup&gt;26&lt;/sup&gt;</td>
<td>Date of registration to emergency department</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>ED Visit - Main Problem&lt;sup&gt;26&lt;/sup&gt;</td>
<td>Most clinically significant diagnosis, condition, problem or circumstance</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>ED Visit - Visit disposition code&lt;sup&gt;26&lt;/sup&gt;</td>
<td>Type of separation from the ambulatory care service</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Hospital Visit - Date of admission&lt;sup&gt;27&lt;/sup&gt;</td>
<td>Date of admission to inpatient care</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Hospital Visit - Diagnosis codes or procedure codes&lt;sup&gt;27&lt;/sup&gt;</td>
<td>ICD diagnosis code and type (most responsible diagnosis)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Hospital Visit - Discharge disposition&lt;sup&gt;27&lt;/sup&gt;</td>
<td>Status of the patient upon leaving the hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Hospital Visit – Special Care Unit&lt;sup&gt;27&lt;/sup&gt;</td>
<td>Type of special care unit where the patient receives critical care, including intensive care units</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Cost-effectiveness</td>
<td>Drug (IV) – total cost</td>
<td>Cost of dose administered to patient (unless calculated from total amount administered and unit cost)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Drug – reimbursed cost</td>
<td>Total cost of drug to a drug program, if different from total cost (i.e., if patient pays co-pay)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Drug (oral) – total cost</td>
<td>Total cost of dispensed drug (unless calculated from total amount dispensed and unit cost)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Drug – Dispensing fees</td>
<td>Total cost of drug dispensing fee to a drug program</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Drug – Compounding fee</td>
<td>Total cost of drug compounding fee to a drug program</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Physician fee – Billing code</td>
<td>Billing code for physician service</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Category</td>
<td>Variables</td>
<td>Description</td>
<td>BC</td>
<td>AB</td>
<td>SK</td>
<td>MB</td>
<td>ON</td>
<td>QB</td>
<td>NB</td>
<td>NS</td>
<td>NL</td>
<td>PEI</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>-----------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>Real-world data elements summary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CanREValue Interim Data Report: 2020 version</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Category</td>
<td>Variables</td>
<td>Description</td>
<td>BC</td>
<td>AB</td>
<td>SK</td>
<td>MB</td>
<td>ON</td>
<td>QB</td>
<td>NB</td>
<td>NS</td>
<td>NL</td>
<td>PEI</td>
</tr>
<tr>
<td>Physician fee – Amount paid</td>
<td>Amount paid for physician service</td>
<td></td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outpatient laboratory and imaging services – Billing code</td>
<td>Billing codes for laboratory and imaging service</td>
<td></td>
<td>✔</td>
<td>?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outpatient laboratory and imaging services – Amount paid</td>
<td>Amount paid for laboratory and imaging service</td>
<td></td>
<td>✔</td>
<td>?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ED cost/resource intensity weight</td>
<td>Resource intensity weight (RIW) for Comprehensive Ambulatory Classification System case mix grouping of the visit; Cost of visit calculated by multiplying the patient visit’s RIW by the cost per weighted case for the jurisdiction and year</td>
<td></td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>Hospitalization cost/resource intensity weight</td>
<td>RIW (see above) for hospital admission case mix group</td>
<td>Cost for visit calculated by multiplying the patient visit’s RIW by the cost per weighted case for the jurisdiction and year</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>?</td>
<td></td>
</tr>
<tr>
<td>Home Care cost</td>
<td>Cost associated with home care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>?</td>
<td></td>
</tr>
<tr>
<td>Complex continuing care cost</td>
<td>Cost of complex continuing care</td>
<td></td>
<td>?</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>?</td>
</tr>
<tr>
<td>Budget Impact</td>
<td>Doses dispensed – Days supplied</td>
<td>Estimated number of days supplied or amounts dispensed – oral medication</td>
<td></td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Treatment dose given</td>
<td>Dose given to patient for IV medication</td>
<td></td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>?</td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body Surface area</td>
<td>Patient’s body surface area at treatment</td>
<td></td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Height</td>
<td>Patient’s height at treatment</td>
<td></td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Weight</td>
<td>Patient’s weight at treatment</td>
<td></td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Patient reported outcomes</td>
<td>Patient reported outcomes</td>
<td>Outcomes such as Edmonton Symptom Assessment Score; Putting Patients First</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** While some of the variables listed in Table 1 can be captured by one data element (e.g. sex), other variables are derived from multiple data elements (e.g. age at first treatment). Details for each variable are listed in the description column.

**Legend:** ICD-O-3 = International Classification of Disease for Oncology third version; IV = Intravenous; ACG = Adjusted clinical group; ED = emergency department; ECOG = Eastern Cooperative Oncology Group; CIHI = Canadian Institute for Health Information; CCI = Canadian Classification of Health Interventions; CCP = Canadian Classification of diagnostic, therapeutic, and surgical procedure (CCP);

- ![Data available and linkable](data_available.png)
- ![Data available and linkable with caveats](data_available_with_caveats.png)
- ![Data availability and linkability to be determined after conducting RWE analysis](data_determination.png)
- ![Data not available or linkable](data_not_available.png)
Table 2: Essential Cancer RWD Table

<table>
<thead>
<tr>
<th>Data element</th>
<th>Description</th>
<th>Database</th>
<th>Database Purpose</th>
<th>Cohort</th>
<th>Covariate</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provincial Patient ID</td>
<td>Unique patient identifier</td>
<td>All databases used</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y - linkage</td>
</tr>
<tr>
<td>Diagnosis Topography code</td>
<td>ICD-O-3 Code from International Classification of Diseases to identify the part of the body affected by disease or the site of origin of the neoplasm</td>
<td>Cancer Registry</td>
<td></td>
<td>Y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnosis Morphology code</td>
<td>ICD-O-3 Code from the morphology section of the International Classification of Diseases to identify the microscopic structure of cells, tissues, and organs</td>
<td>Cancer Registry</td>
<td></td>
<td>Y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of diagnosis</td>
<td>Diagnosis date – the date of first diagnosis of the primary site of cancer</td>
<td>Cancer Registry</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>Drug Identifier – Drug name/code/regimen/DIN</td>
<td>Drug name, regimen, or DIN (Health Canada identifier) to identify study drugs, prior and subsequent treatments</td>
<td>Treatment/claims</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y - Survival</td>
</tr>
<tr>
<td>Treatment date</td>
<td>Date of treatment for particular drug – IV medication</td>
<td>Treatment/claims</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y - Budget Impact</td>
</tr>
<tr>
<td>Treatment dose given</td>
<td>Dose given to patient for IV medication</td>
<td>Treatment/claims</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug (IV) - total cost</td>
<td>Cost of dose administered to patient (unless calculated from total amount administered and unit cost)</td>
<td>Treatment/claims</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y - Costs</td>
</tr>
<tr>
<td>Dispensing date</td>
<td>Dispensing date for particular drug – oral medication</td>
<td>Treatment/claims</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td>Y - Budget Impact</td>
</tr>
<tr>
<td>Doses dispensed – Days supplied</td>
<td>Estimated number of days supplied or amounts dispensed – oral medication</td>
<td>Treatment/claims</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug (oral) – total cost</td>
<td>Total cost of dispensed drug (unless calculated from total amount dispensed and unit cost)</td>
<td>Treatment/claims</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex/Gender</td>
<td>Patient sex</td>
<td>Population Registry</td>
<td></td>
<td>Y</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>Date of birth</td>
<td>Date of birth</td>
<td>Population Registry</td>
<td></td>
<td>Y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal code</td>
<td>To determine categories of neighbourhood income quintile, rurality</td>
<td>Population Registry, Census data (2016)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of death</td>
<td>Date of death</td>
<td>Population Registry, Vital Statistics</td>
<td></td>
<td>Y</td>
<td></td>
<td>Y - Survival</td>
</tr>
<tr>
<td>Surgical Intervention code CCP/CCI Code</td>
<td>The CIHI CCP/CCI procedure code describing the procedure administered to the patient</td>
<td>CIHI-DAD</td>
<td></td>
<td>Y</td>
<td></td>
<td>Y - Costs</td>
</tr>
<tr>
<td>Surgical resection date</td>
<td>Date of surgical intervention associated with CCP/CCI codes</td>
<td>CIHI-DAD</td>
<td></td>
<td>Y</td>
<td></td>
<td>Y - Costs</td>
</tr>
<tr>
<td>Discharge date of hospitalisation</td>
<td>Discharge date</td>
<td>CIHI-DAD</td>
<td></td>
<td>Y</td>
<td></td>
<td>Y - Safety</td>
</tr>
</tbody>
</table>
## Real-world data elements summary

### CanREValue Interim Data Report: 2020 version

<table>
<thead>
<tr>
<th>Data element</th>
<th>Description</th>
<th>Database</th>
<th>Purpose</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of admission of hospitalisation</td>
<td>Date of admission to acute care</td>
<td>CIHI-DAD</td>
<td>Y</td>
<td>Y</td>
<td>Y - Safety</td>
</tr>
<tr>
<td>Visit disposition code</td>
<td>Status of the patient upon leaving the hospital</td>
<td>CIHI-DAD</td>
<td>Y</td>
<td>Y</td>
<td>Y - Safety</td>
</tr>
<tr>
<td>Main problem</td>
<td>ICD diagnosis code and type (most-responsible diagnosis)</td>
<td>CIHI-DAD</td>
<td>Y</td>
<td>Y</td>
<td>Y - Safety</td>
</tr>
<tr>
<td>Hospitalization/SDS - RIW</td>
<td>Resource intensity weight (RIW) to calculate cost</td>
<td>CIHI-DAD/NACRS</td>
<td>Y</td>
<td>-</td>
<td>Y - Costs</td>
</tr>
<tr>
<td>Hospitalization/SDS – Cost per Weighted Case</td>
<td>Cost per weighted case</td>
<td>CIHI-DAD</td>
<td>Y</td>
<td>-</td>
<td>Y - Costs</td>
</tr>
<tr>
<td>Physician Billing</td>
<td>Physician billing code (or amount paid)</td>
<td>Physician billings database</td>
<td></td>
<td>Y</td>
<td>Y - Costs</td>
</tr>
<tr>
<td>Physician Service date</td>
<td>Date of physician visit</td>
<td>Physician billings database</td>
<td></td>
<td>Y</td>
<td>Y - Costs</td>
</tr>
<tr>
<td>Radiotherapy Use</td>
<td>Identifies patients who received radiotherapy</td>
<td>Radiation database</td>
<td>Y</td>
<td>Y</td>
<td>Y - Costs</td>
</tr>
<tr>
<td>Radiotherapy - Intent</td>
<td>The intention of radiotherapy treatment as determined by the radiation oncologist</td>
<td>Radiation database</td>
<td>Y</td>
<td>-</td>
<td>Y - Costs</td>
</tr>
<tr>
<td>Radiotherapy - visit date</td>
<td>The patient’s visit date for radiotherapy</td>
<td>Radiation database</td>
<td>Y</td>
<td>Y</td>
<td>Y - Costs</td>
</tr>
</tbody>
</table>

**Note:** The first two columns list the data elements and a brief description of each data elements. The third column provides the type of database(s) that the data elements may be located in. The fourth, fifth, and sixth columns provide information on what the variable may be used for among cohort creation, demographic or clinical covariate, or outcome definition. “Y” dictates that the variable will be used for purpose listed in the column header.

**Legend:** DIN = Drug Identification Number; ICD-O-3 = International Classification of Disease for Oncology third version; IV = Intravenous; ACG = Adjusted clinical group; ED = emergency department; ECOG = Eastern Cooperative Oncology Group; CIHI = Canadian Institute for Health Information; CCI = Canadian Classification of Health Interventions; CCP = Canadian Classification of diagnostic, therapeutic, and surgical procedure (CCP); DAD = Discharge Abstract Database; NACRS = National Ambulatory Care Reporting System;
Section III: Provincial capability and capacity assessment

This section outlines the capability and capacity assessment to conduct RWE studies by each province. Data experts from each province were asked to conduct the assessments. First, provinces were asked to examine the capability to conduct an RWE analysis on different types of outcomes (e.g. effectiveness) based on the available data elements. Second, we asked the provinces to assess the anticipated time required to perform each step of the analysis based on currently available resources and based on dedicated personnel and funding.

**Capability Assessment:**

Data experts were asked to evaluate the capability of conducting an RWE analysis on the different outcomes based on the currently available data elements. Given differences in funding models and data holdings in some provinces based on setting, we asked the provincial data experts to conduct this assessment for both intravenous and oral drugs. A province’s capability to conduct a RWE project based on currently available data depends on the outcome of interest and the study drugs being evaluated.

**Table 3:** Capability assessment for conducting a comparative analysis on intravenous cancer drugs

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>BC</th>
<th>AB</th>
<th>SK</th>
<th>MB</th>
<th>ON</th>
<th>QB</th>
<th>NB</th>
<th>NS</th>
<th>NFL</th>
<th>PEI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effectiveness (survival)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety &amp; Toxicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budget Impact (public payer’s perspective)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost-Effectiveness Analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient reported outcomes, quality of life</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 4:** Capability assessment for conducting a comparative analysis on oral drugs:

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>BC</th>
<th>AB</th>
<th>SK</th>
<th>MB</th>
<th>ON</th>
<th>QB</th>
<th>NB</th>
<th>NS</th>
<th>NFL</th>
<th>PEI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effectiveness (survival)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety &amp; Toxicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budget Impact (public payer’s perspective)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost-Effectiveness Analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient reported outcomes, quality of life</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Analysis can be completed
- Analysis can be completed with caveats
- Analysis cannot be completed
**Capacity Assessment:**

Data experts evaluated how long it would take to complete each step of the RWE analysis based on two scenarios: i) currently available resources, and ii) dedicated personnel and funding.

**Table 5:** How long would it take to complete these analyses *based on currently available resources*?

<table>
<thead>
<tr>
<th>Analysis</th>
<th>BC</th>
<th>AB</th>
<th>SK</th>
<th>MB</th>
<th>ON</th>
<th>QB</th>
<th>NB</th>
<th>NS</th>
<th>NFL</th>
<th>PEI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cohort creation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Effectiveness (survival)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety &amp; Toxicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budget Impact (public payer’s perspective)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost-Effectiveness Analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient reported outcomes, quality of life</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 6:** How long would it take to complete these analyses *if there is dedicated personnel and funding*? (i.e., based on data access issues only)

<table>
<thead>
<tr>
<th>Analysis</th>
<th>BC</th>
<th>AB</th>
<th>SK</th>
<th>MB</th>
<th>ON</th>
<th>QB</th>
<th>NB</th>
<th>NS</th>
<th>NFL</th>
<th>PEI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cohort creation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Effectiveness (survival)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety &amp; Toxicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budget Impact (public payer’s perspective)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost-Effectiveness Analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient reported outcomes, quality of life</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Analysis can be completed within 3 to 6 months
- Analysis can be completed within 6 to 12 months
- Analysis cannot be completed or takes more than 12 months to complete

With the currently available resources, few provinces are able to complete the analysis within 12 months.

**Next steps**

The CanREValue Data WG will evaluate the accessibility and availability of these data elements by conducting a RWE project on an intravenous and oral cancer drugs across the provinces. Based on our findings from conducting the real-world studies and the stakeholder consultations, we will iteratively update the contents of this report accordingly. A final report of the updated data holdings and elements will be released after the completion of our multi-province real-world evaluations of cancer drugs. Through this iterative process, we will build a fundamental understanding of the data assets that can be used to conduct RWE analysis.
References:


